JMP Securities assumed coverage on shares of Menlo Therapeutics (NASDAQ:MNLO) in a research note issued to investors on Tuesday, February 20th, MarketBeat.com reports. The firm issued an outperform rating and a $44.00 price target on the stock.
Other analysts also recently issued reports about the company. Jefferies Group started coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They set a buy rating and a $41.00 price target for the company. Guggenheim initiated coverage on Menlo Therapeutics in a research report on Monday, February 19th. They set a buy rating and a $52.00 price target for the company. Finally, Piper Jaffray Companies initiated coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They issued an overweight rating and a $48.00 target price for the company.
Menlo Therapeutics (NASDAQ:MNLO) traded down $1.98 during mid-day trading on Tuesday, hitting $31.42. The stock had a trading volume of 147,519 shares, compared to its average volume of 151,973. Menlo Therapeutics has a 52 week low of $20.50 and a 52 week high of $39.86.
About Menlo Therapeutics
Menlo Therapeutics Inc is a United States-based biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough.
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.